Memory Pharmaceuticals Receives Nasdaq No... ( MONTVALE N.J. April 4 2008 /- Mem...)

Memory Pharmaceuticals Receives Nasdaq Notification

Date:4/4/2008

MONTVALE, N.J., April 4, 2008 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that on April 2, 2008, it received notice from The Nasdaq Stock Market stating that the Company is no longer in compliance with the minimum $10.0 million stockholders' equity requirement for continued listing on The Nasdaq Global Market under Marketplace Rule 4450(a)(3). As reported in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, the Company's stockholders' equity was $8.3 million.

In the letter, Nasdaq staff requested that the Company provide, on or before April 17, 2008, a plan to achieve and sustain compliance with all of The Nasdaq Global Market listing requirements, including the minimum stockholders' equity requirement, and the time frame required to complete the plan. The Company is preparing its plan for submission to Nasdaq by the specified date.

If, after the conclusion of the Nasdaq staff's review process, the staff determines that the Company has not presented an appropriate definitive plan, the staff will provide the Company with a written notification that its securities will be delisted from The Nasdaq Global Market. The Company may then appeal the Nasdaq staff's delisting determination to the Nasdaq Listing Qualifications Panel.

The notification letter has no effect at this time on the continued listing of Memory Pharmaceuticals' common stock on the Nasdaq Global Market.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
2. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
3. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
4. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
6. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
7. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
8. ASU researchers improve memory devices using nanotech
9. BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants
10. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
11. Scientists synthesize memory in yeast cells

Post Your Comments:

(Date:11/30/2009)... , , ROCKVILLE, Md., Nov. 30 /PRNewswire...unced today it has completed enrollment in the Pha...luenza (2008/2009 recommended strains) VLP vaccine...der (older adults). This randomized, double-blind... tolerability and immunogenicity of two different ...

(Date:11/30/2009)... , , SEATTLE, Nov. 30 /PRNewswire-F... and MTA: CTIC) announced today that its new class...s-platinates, demonstrated a stronger anti-tumor p...e platinum-based compounds as well as the ability ...nes. The results were presented in a paper titled...

(Date:11/30/2009)... , , LONDON, November 30 /PR...logics company, was named Europe,s fastest growing...nt company in the Deloitte,2009 Technology Fast 50..., This annual ranking is based on a companies,...chieved a rate of 8,318% over this period. This,ac...

(Date:11/28/2009)... , The Vanuatu National A...h its Second National Communication (SNC) Project ...ervices and CLIMsystems Ltd. of New Zealand have g...rise results that will form the background for the...ns Framework Convention on Climate Change (UNFCCC)...

Breaking Biology Technology:NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2 NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3 NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4 New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2 New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3 ApaTech is Europe's Fastest Growing Lifescience Company 2 ApaTech is Europe's Fastest Growing Lifescience Company 3 ApaTech is Europe's Fastest Growing Lifescience Company 4 Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2 Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3 Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4

[0] NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults [0] New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents [0] ApaTech is Europe's Fastest Growing Lifescience Company [0] Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM

...4 Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), ...g,developing and commercializing proprietary produ...setting, announced today that the company,s,Presid...mpany,s corporate,overview at the following invest...cialty Pharmaceuticals Conference at the South...

...nues - a record $35.5 million vs. $24.7 million in...43.4%, Q2 2008 Diluted Net Income per Share - $0... increase of 62.5% Q2 2008 Operating Inco...New Bookings of $49.0 million vs. $34.5 million in...gy,Inc. (eRT), (Nasdaq: ERES ), a leading provide...

...., Aug. 4 Telik, Inc.,(Nasdaq: TELK ) announced ...ebcast will be held on Monday, August 11, 2008 at ...llowing the release earlier that day of the,compan... June 30, 2008., The conference call will be acce...m or by telephone at 800-553-5260 or 612-332-0720...

Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008 eResearchTechnology Reports Second Quarter 2008 Results Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast

(Date:11/30/2009)...Those extra helpings of gravy and dessert at the h...line than previously thought. According to a new r...ASEB Journal ( http://www.fasebj.org ), a diet th...n genes that ultimately cause our bodies to store ...a double-whammy as the already difficult task of c...

(Date:11/30/2009)... This release is available in German . , Th...laborative Research Centres as of 1 January 2010. ...ants Committee in Bonn. The new centres will initi...million. In addition, 20 percent overhead funding ...project. The centres, research topics range from m...

(Date:11/30/2009)...HOBOKEN, N.J. - The inaugural Global Conference o...r 3-4, 2009, in Washington, DC, focuses on the con...rises of critical importance to society. , T...of research activity around targeted complex syste...s year,s topic includes Critical Infrastructure Sy...

[0] Happy holidays from the groaning board; Western diets turn on fat genes [0] DFG approves funding for 17 new collaborative research centers [0] First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4

...just the climate that is struggling with what huma...eling the pressure as well, according to Professor...Takes a Genome: How a Clash Between Our Genes and ...from UQ,s School of Biological Sciences, suggests ...cancer and Alzheimer,s are due to human genes bein...

...f leading UK scientists and social scientists led ...y of Edinburgh, calls for joined-up thinking on th... gold. The world is waking up to the potential of ...o carbon sinks, there is growing talk of plants re...my. , But such fame comes at a price. , Recent...

...a from the satellite-based MIPAS and GOME-2 instru... important bromine species in the atmosphere. Thes...understand sources of ozone-depleting species and ...istry. , Despite the detection of bromine monoxid...ne nitrate (BrONO2) was first observed in 2008 whe...

Other Biology News:'It takes a genome: How a clash between our genes and modern life is making us sick' 2 Plants are political hot potatoes 2 European satellites provide new insight into ozone-depleting species 2

'It takes a genome: How a clash between our genes and modern life is making us sick'Plants are political hot potatoes European satellites provide new insight into ozone-depleting species

Rabbit anti-Alpha-4 AbVantage Pack Polyclonal Antibody, Unconjugated from Bethyl Laboratories

Amino Acid Mixture Minus Cysteine from Promega

Goat Anti-Mouse Aminopeptidase P2 / XPNPEP2 Polyclonal Antibody, Unconjugated from R&D Systems

CometSlide from R&D Systems

Biology Products:

Rabbit anti-Alpha-4 AbVantage Pack Polyclonal Antibody, Unconjugated from Bethyl Laboratories Amino Acid Mixture Minus Cysteine from Promega Goat Anti-Mouse Aminopeptidase P2 / XPNPEP2 Polyclonal Antibody, Unconjugated from R&D Systems CometSlide from R&D Systems

Memory Pharmaceuticals Receives Nasdaq No...( MONTVALE N.J. April 4 2008 /- Mem...)